Drug intelligence / Profile preview

KVA923

Development stage: Unknown
Lead developer: Sanofi
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies

Overview

KVA923 is a T-cell immunotherapy that was being developed by Kiadis Pharma as a lead asset in its immuno-oncology pipeline. It is currently in Phase II/III clinical trials for the treatment of acute myeloid leukemia. Sanofi acquired Kiadis Pharma, gaining full control of KVA923 and other assets, as part of its strategic focus on oncology and cell/gene therapies.

Beyond the preview

Go deeper on KVA923.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KVA923.

Explore the full profile